<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05031949</url>
  </required_header>
  <id_info>
    <org_study_id>2021-S087</org_study_id>
    <nct_id>NCT05031949</nct_id>
  </id_info>
  <brief_title>Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma</brief_title>
  <official_title>A Single-center, Single-arm, Non-randomized Clinical Study to Evaluate the Efficacy and Safety of Hyperbaric Oxygen Therapy Plus Camrelizumab as a Second-line Treatment in Advanced/Metastatic Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>bixiangzhang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tongji Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the efficacy and safety of hyperbaric oxygen therapy&#xD;
      plus Camrelizumab as a second-line treatment in patients with advanced hepatocellular&#xD;
      carcinoma who have failed at least 1 previous treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 30, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>A Phase 1b, Open-Label, Single-Arm Study to explore the efficacy and safety of hyperbaric oxygen therapy plus Camrelizumab as a second-line treatment in patients with advanced hepatocellular carcinoma who have failed at least 1 previous treatment.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) per RECIST v1.1</measure>
    <time_frame>up to 12 months.</time_frame>
    <description>ORR defined as the proportion of subjects who achieved a complete response (disappearance of all target lesions) or a partial response (≥ 30% decrease in the sum of the longest diameters of target lesions) based on RECIST v1.1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival based on RECIST v1.1</measure>
    <time_frame>Time from first treatment to the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months</time_frame>
    <description>Progression-free survival defined as the time from the first day of taking study drug to death or disease progression by RECIST v1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response Rate per RECIST v1.1</measure>
    <time_frame>up to 12 months</time_frame>
    <description>time from the date of CR or PR until PD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate per RECIST v1.1</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Disease control rate (DCR)=CR + PR + stable disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Duration from the date of initial treatment with hyperbaric oxygen therapy plus Camrelizumab to the date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects with one or more adverse events as assessed by CTCAE 5.0</measure>
    <time_frame>From screening through 30-35 days after end of treatment, up to 12 months</time_frame>
    <description>Safety and tolerability of hyperbaric oxygen therapy plus Camrelizumab as assessed by the frequency, duration, and severity of adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Combinational Immunotherapy</condition>
  <condition>Hepatocellular Carcinoma Non-Resectable</condition>
  <condition>Hyperbaric Oxygen Therapy</condition>
  <arm_group>
    <arm_group_label>Hyperbaric oxygen therapy plus Camrelizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive Camrelizumab intravenous at the dose 3mg/kg on Day 1 every 3 weeks, and breath pressurized (0.25 MPa) 100% oxygen (O2) indirectly by a head hood or mask for 60 minutes in multiplace chambers at Day 1 of every week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>hyperbaric oxygen therapy plus Camrelizumab</intervention_name>
    <description>Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody</description>
    <arm_group_label>Hyperbaric oxygen therapy plus Camrelizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects volunteer to participate in the study and agree to sign the informed consent&#xD;
             with good compliance and follow-up.&#xD;
&#xD;
          2. Subjects are 18 years old or older when signing the informed consent and gender is not&#xD;
             limited.&#xD;
&#xD;
          3. Histologically confirmed HCC in advanced stage; not suitable to surgery or local&#xD;
             regional treatment; with at least one measurable lesion per RECIST 1.1&#xD;
&#xD;
          4. Failed or intolerable to at least one prior systemic treatment for advanced HCC&#xD;
&#xD;
          5. With at least one assessment lesion according to the RESIST v1.1 criteria.&#xD;
&#xD;
          6. Estimated survival time ≥ 12 weeks.&#xD;
&#xD;
          7. The ECOG score is 0-1 within 1 week before enrollment.&#xD;
&#xD;
          8. Adequate organ function, including:&#xD;
&#xD;
               1. Whole blood cell examination (no blood transfusion within 14 days, no G-CSF use&#xD;
                  and no drugs use): Hb≥90g/L, ANC≥1.5×10*9/L, PLT≥70×10*9/L;&#xD;
&#xD;
               2. Biochemical examination (no ALB infused within 14 days): ALB≥29 g/L, ALT and&#xD;
                  AST&lt;5×ULN, TBIL≤1.5×ULN, creatinine≤1.5×ULN, and prothrombin time or INR&#xD;
                  ≤1.5×ULN;&#xD;
&#xD;
               3. thyroid stimulating hormone (TSH) within the normal range. If the baseline TSH&#xD;
                  exceeds the normal range, subjects with total T3 (or FT3) and FT4 within the&#xD;
                  normal range can also be enrolled;&#xD;
&#xD;
          9. Without biliary obstruction. Subjects who need biliary stent implantation must be&#xD;
             completed at least 7 days before enrollment&#xD;
&#xD;
         10. Male or female participants of childbearing potential must be willing to use an&#xD;
             adequate method of contraception starting with the first dose of study drug through 60&#xD;
             days for female subjects and 120 days for male subjects after the last dose of study&#xD;
             drug&#xD;
&#xD;
         11. Subjects with asymptomatic or stable brain metastases after local treatment are&#xD;
             allowed to be included as long as they meet the following conditions:&#xD;
&#xD;
               1. measurable lesions outside the central nervous system;&#xD;
&#xD;
               2. No central nervous system symptoms or no aggravation of symptoms for at least 2&#xD;
                  weeks;&#xD;
&#xD;
               3. Those who do not need glucocorticoid treatment or stop glucocorticoid treatment&#xD;
                  within 7 days before the administration of the first study drug;&#xD;
&#xD;
               4. Patients were allowed to receive palliative radiotherapy, but the end time of&#xD;
                  radiotherapy was within 7 days before the administration of the first study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects with one or more than one of the following criteria should be excluded&#xD;
&#xD;
          1. Subjects has contraindications of hyperbaric oxygen use, including pneumothorax,&#xD;
             mediastinal edema, multiple rib fractures, open trauma of chest wall, vacuolar&#xD;
             pulmonary tuberculosis with hemoptysis, pulmonary bullae, active internal bleeding and&#xD;
             hemorrhagic diseases;&#xD;
&#xD;
          2. Subjects with other malignant tumors in the past 5 years (radical skin basal cell&#xD;
             carcinoma, skin squamous epithelial carcinoma, and / or radical resection of carcinoma&#xD;
             in situ were not included);&#xD;
&#xD;
          3. subjects are currently participating in other interventional clinical studies, or&#xD;
             received any topical treatment within 4 weeks prior to the study, including but not&#xD;
             limited to surgery, radiotherapy, hepatic artery embolization, TACE, hepatic artery&#xD;
             perfusion, radiofrequency ablation, cryoablation or percutaneous ethanol injection;&#xD;
&#xD;
          4. systemic treatment with traditional Chinese medicine with anti-tumor indications or&#xD;
             drugs with immunomodulatory effect (including thymosin, interferon and interleukin,&#xD;
             except for local use to control pleural effusion) within 2 weeks before the first&#xD;
             administration;&#xD;
&#xD;
          5. Diagnosis of immunodeficiency or systemic steroid therapy or any form of&#xD;
             immunosuppressants therapy within 7 days prior to this study. A physiological dose of&#xD;
             corticosteroids (no more than 7.5 mg/d prednisone or equivalent) can be approved after&#xD;
             clinical evaluation;&#xD;
&#xD;
          6. Pleural effusion or Ascites with clinical symptoms which requires pleural or abdominal&#xD;
             puncture or drainage therapy;&#xD;
&#xD;
          7. Subjects have organ transplantation history.&#xD;
&#xD;
          8. Subjects are allergic to the active ingredients or excipients of Camrelizumab;&#xD;
&#xD;
          9. Subjects with multiple factors affecting oral drugs (such as inability to swallow,&#xD;
             post gastrointestinal resection, chronic diarrhea and intestinal obstruction);&#xD;
&#xD;
         10. Not fully recovered from toxicity and / or complications caused by any intervention&#xD;
             before starting treatment (i.e. ≤ grade 1 or reaching baseline, excluding fatigue or&#xD;
             hair loss);&#xD;
&#xD;
         11. Known history of human immunodeficiency virus (HIV) infection (i.e. HIV 1 / 2 antibody&#xD;
             positive);&#xD;
&#xD;
         12. Untreated active hepatitis B (defined as HBsAg positive and HBV-DNA copy number at the&#xD;
             same time was higher than the upper limit of normal value in the laboratory of the&#xD;
             research center).Note: hepatitis B patients who meet the following criteria can also&#xD;
             be enrolled:&#xD;
&#xD;
               1. Before the first administration, the HBV viral load was less than 1000 copies /&#xD;
                  ml (200 IU / ml). Subjects should receive anti HBV treatment throughout the study&#xD;
                  chemotherapy treatment to avoid virus reactivation;&#xD;
&#xD;
               2. For subjects with anti HBC (+), HBsAg (-), anti HBS (-) and HBV viral load (-),&#xD;
                  preventive anti HBV treatment is not required, but virus reactivation needs to be&#xD;
                  closely monitored.&#xD;
&#xD;
         13. Active HCV infected subjects (HCV antibody positive and HCV-RNA level higher than the&#xD;
             lower limit of detection);&#xD;
&#xD;
         14. Live vaccine was administered within 30 days before the first administration (cycle 1,&#xD;
             day 1);Note: it is allowed to receive inactivated virus vaccine for injection against&#xD;
             seasonal influenza within 30 days before the first administration; However, live&#xD;
             attenuated influenza vaccines administered intranasal are not allowed.&#xD;
&#xD;
         15. Female subjects who are pregnant, breastfeeding or refuse contraception.&#xD;
&#xD;
         16. Subjects have any serious or uncontrollable systemic diseases, such as:&#xD;
&#xD;
               1. There are significant abnormalities in rhythm, conduction or morphology of&#xD;
                  resting ECG and the symptoms are serious and difficult to control, such as&#xD;
                  complete left bundle branch block, heart block above grade II, ventricular&#xD;
                  arrhythmia or atrial fibrillation;&#xD;
&#xD;
               2. Unstable angina pectoris, congestive heart failure, chronic heart failure with&#xD;
                  New York Heart Association (NYHA) grade ≥ 2;&#xD;
&#xD;
               3. Any arterial thrombosis, embolism or ischemia, such as myocardial infarction,&#xD;
                  unstable angina pectoris, cerebrovascular accident or transient ischemic attack,&#xD;
                  occurred within 6 months before enrollment;&#xD;
&#xD;
               4. Poor blood pressure control (systolic blood pressure &gt; 140 mmHg, diastolic blood&#xD;
                  pressure &gt; 90 mmHg);&#xD;
&#xD;
               5. A history of noninfectious pneumonia requiring glucocorticoid treatment within 1&#xD;
                  year before the first administration, or the current presence of clinically&#xD;
                  active interstitial lung disease;&#xD;
&#xD;
               6. Active pulmonary tuberculosis;&#xD;
&#xD;
               7. There are active or uncontrolled infections requiring systemic treatment;&#xD;
&#xD;
               8. There were clinically active diverticulitis, abdominal abscess and&#xD;
                  gastrointestinal obstruction;&#xD;
&#xD;
               9. Liver diseases such as cirrhosis, decompensated liver disease, acute or chronic&#xD;
                  active hepatitis;&#xD;
&#xD;
              10. Diabetes was poorly controlled (fasting blood glucose (FBG) &gt; 10mmol/L).&#xD;
&#xD;
              11. Urine routine examination showed that urinary protein was ≥ + +, and the 24-hour&#xD;
                  urinary protein was confirmed to be more than 1.0 G;&#xD;
&#xD;
              12. Subjects with mental disorders and unable to cooperate with treatment;&#xD;
&#xD;
         17. Subjects are unsuitable for participation in this research after comprehensive&#xD;
             assessment by the researchers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ze-yang Ding, M.D.</last_name>
    <phone>+86-13407156200</phone>
    <email>dingzyang@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hepatic Surgery Center, Tongji Hospital, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ze-yang Ding, M.D.</last_name>
      <phone>+8613407156200</phone>
      <email>dingzyang@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 31, 2021</study_first_submitted>
  <study_first_submitted_qc>September 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2021</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Tongji Hospital</investigator_affiliation>
    <investigator_full_name>bixiangzhang</investigator_full_name>
    <investigator_title>Prof.; M. D.; Ph. D.</investigator_title>
  </responsible_party>
  <keyword>hyperbaric oxygen therapy</keyword>
  <keyword>Camrelizumab</keyword>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>second-line treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

